


PHARMACEUTICAL 2020



XBiotech Inc. Rank 1 of 362







PHARMACEUTICAL 2020



XBiotech Inc. Rank 1 of 362



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1,006% points. The greatest weakness of XBiotech Inc. is the variable Revenues, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is 808%, being 1,111% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	716,263
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,190
Liabilities, Non-Current	0
Other Assets	75,443
Other Compr. Net Income	149
Other Expenses	49,824
Other Liabilities	1,056
Other Net Income	749,686
Property and Equipment	25,171
Research and Development	24,090
Revenues	0
Selling, General and Administrative Expense	7,143

Output Variable	Value in 1000 USD
Assets	816,877
Liabilities	61,246
Expenses	81,057
Stockholders Equity	755,631
Net Income	668,629
Comprehensive Net Income	668,704
Economic Capital Ratio	808%

